Lisamarie A. Collins
Partner
Dr. Lisamarie Collins partners with biotechnology and other life sciences companies to build patent portfolios designed to protect innovation, address competitive threats, and support business growth. Drawing on a Ph.D. in physiology and years at the research bench, she guides clients through the intellectual property life cycle, from protecting early-stage innovation to commercialization, licensing, and the diligence that supports investments and exits.
Lisamarie advises clients on patent procurement and portfolio management. Her work includes patentability assessments, U.S. and foreign patent preparation and prosecution, global portfolio strategy, noninfringement, freedom-to-operate and validity opinions, due diligence, and licensing. She works with companies developing technologies that include artificial intelligence-based diagnostic platforms, antisense and small interfering RNA (siRNA) oligonucleotides, immunotherapies, molecular and cell biology, cell-based therapeutics, and cancer therapies. She is a member of the Chemical, Biotechnology & Pharmaceutical Practice and the Health Care & Life Sciences and Innovative Technology Sectors.
Lisamarie has considerable experience in agricultural biotechnology and microbe-based technologies. She counsels innovators developing animal and plant genetics, probiotics, fermented food products, and engineered microbial consortia. She also advises clients on the distinctive patenting challenges presented by living systems, natural products, and biological deposits. Her work includes protecting strains and consortia alongside their methods of use, navigating overlapping patent protection, and developing portfolios that account for the regulatory and labeling environment in which agricultural and food products reach market.
Lisamarie also advises clients developing therapeutics directed at mitochondrial function, lipoproteins, and lipid metabolism, building on her doctoral research in this area. Her therapeutics work also encompasses cancer treatments, including immunotherapies and oligonucleotide-based approaches. Across these areas, she helps clients address the intersection of patent strategy and regulatory requirements. She has written about this intersection in the context of laboratory-developed tests and how statements in U.S. Food and Drug Administration (FDA) submissions may later affect patent prosecution and enforcement. Lisamarie distills complex, interdisciplinary technologies into practical guidance that scientists, in-house counsel, and business leaders can use.
Lisamarie also advises private capital clients, including a private equity sponsor and several of its portfolio companies. She leads intellectual property due diligence for prospective investments, identifying ownership, chain-of-title, freedom-to-operate, open source, and licensing risks and translating the findings into deal terms. She continues advising portfolio companies after closing, including on intellectual property readiness for initial public offerings (IPOs).
Lisamarie has spent her entire legal career at Foley. She began as a summer associate, later worked as a law clerk, and then joined the firm as an attorney. Before beginning her legal career, she conducted research and taught physiological and biological sciences at the Medical College of Wisconsin where her published research characterized human plasma lipoproteins using liquid chromatography and tandem mass spectrometry. That research continues to inform her counsel to clients developing lipoprotein-directed therapeutics.
A lifelong Wisconsinite who earned all three of her degrees in Milwaukee, Lisamarie remains deeply invested in the region’s life sciences community and the institutions that shape it.
Awards and Recognition
- The Best Lawyers® in America Ones to Watch – Intellectual Property Law (2021-2024); Technology Law (2021-2024)
Affiliations
- Member, State Bar of Wisconsin Intellectual Property Section
Presentations and Publications
- Co-author, “LDT Proposals: Concerns about the FDA’s proposal LDT regulations on test providers and patients,” Advanced Healthcare Network for Laboratory (March 14, 2016)
- Co-author, “Laboratory Developed Tests (LDTs) – An emerging area of FDA regulation,” Advance Healthcare Network for Laboratory (December 28, 2015)
- Author, “Dueling Records: Are Statements in Your 510(k) Putting Your Patents at Risk?” BNA Bloomberg 210 (October 30, 2015)
- Author, “Copyrightable Works in the Undergraduate Student Context: An Examination of the Issues,” Marquette Intellectual Property Law Review, 285 (2013)
- Co-author, “Integrated approach for the comprehensive characterization of lipoproteins from human plasma using FPLC and nano-HPLC-tandem mass spectrometry,” Physiol Genomics, 40: 208-215 (2010)
- Co-author, “Quantitative comparison of lipoprotein fractions derived from human plasma and serum by liquid chromatography-tandem mass spectrometry,” Proteome Science, 8:42 (2010)